ARMATA PHARMACEUTICALS, INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
ARMATA PHARMACEUTICALS, INC. (ARMP) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 17.06 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2026-08-12
- ARMATA PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-06-30 was 17.06M shares, a 56.96% decline year-over-year.
- ARMATA PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2026-03-31 was 42.09M shares, a 160.90% increase year-over-year.
- ARMATA PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-06-30 was 39.64M shares.
- ARMATA PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2025-03-31 was 16.13M shares, a 65.10% decline year-over-year.
- ARMATA PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2025 was 40.11M shares, a 71.84% increase from fiscal 2024.
- ARMATA PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2024 was 23.34M shares, a 46.98% decline from fiscal 2023.
- ARMATA PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2023 was 44.02M shares, a 83.19% increase from fiscal 2022.
- ARMATA PHARMACEUTICALS, INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2022 was 24.03M shares, a 25.09% increase from fiscal 2021.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month as first filed | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 17.06M shares 10-Q · filed 2026-08-12 | 42.36M shares 10-Q · filed 2026-08-12 | ||||||
| 2026-03-31 | 42.09M shares 10-Q · filed 2026-05-13 | |||||||
| 2025-12-31 | 40.11M shares 10-K · filed 2026-03-25 | |||||||
| 2025-09-30 | 39.92M shares 10-Q · filed 2025-11-12 | |||||||
| 2025-06-30 | 39.64M shares 10-Q · filed 2026-08-12 | 39.64M shares 10-Q · filed 2026-08-12 | ||||||
| 2025-03-31 | 16.13M shares 10-Q · filed 2026-05-13 | |||||||
| 2024-12-31 | 23.34M shares 10-K · filed 2026-03-25 | |||||||
| 2024-09-30 | 46.03M shares 10-Q · filed 2024-11-13 | |||||||
| 2024-06-30 | 24.30M shares 10-Q · filed 2024-08-13 | |||||||
| 2024-03-31 | 46.22M shares 10-Q · filed 2024-05-07 | |||||||
| 2023-12-31 | 44.02M shares 10-K · filed 2025-03-21 | |||||||
| 2023-09-30 | 23.53M shares 10-Q · filed 2023-11-14 | |||||||
| 2023-06-30 | 23.82M shares 10-Q · filed 2023-08-14 | |||||||
| 2023-03-31 | 24.04M shares 10-Q · filed 2023-05-11 | |||||||
| 2022-12-31 | 24.03M shares 10-K · filed 2024-03-21 | |||||||
| 2022-09-30 | 24.06M shares 10-Q · filed 2023-11-14 | |||||||
| 2022-06-30 | 24.06M shares 10-Q · filed 2023-08-14 | |||||||
| 2022-03-31 | 23.61M shares 10-Q · filed 2023-05-11 | |||||||
| 2021-12-31 | 19.21M shares 10-K · filed 2023-03-16 | |||||||
| 2021-09-30 | 19.24M shares 10-Q · filed 2022-11-09 | |||||||
| 2021-06-30 | 19.17M shares 10-Q · filed 2022-08-11 | |||||||
| 2021-03-31 | 19.14M shares 10-Q · filed 2022-05-12 | |||||||
| 2020-12-31 | 12.54M shares 10-K · filed 2022-03-17 | |||||||
| 2020-09-30 | 12.26M shares 10-Q · filed 2021-11-10 | |||||||
| 2020-06-30 | 12.28M shares 10-Q · filed 2020-08-13 | 12.28M shares 10-Q · filed 2021-08-12 | ||||||
| 2020-03-31 | 12.25M shares 10-Q · filed 2021-05-13 | |||||||
| 2019-12-31 | 3.47M shares 10-K · filed 2021-03-18 | |||||||
| 2019-09-30 | 3.52M shares 10-Q · filed 2019-11-12 | 3.52M shares 10-Q · filed 2020-11-12 | ||||||
| 2019-06-30 | 3.61M shares 10-Q · filed 2020-08-13 | 3.61M shares 10-Q · filed 2019-08-14 | ||||||
| 2019-03-31 | 553.32K shares 10-Q · filed 2020-05-14 | 27.34M shares 10-Q · filed 2019-05-06 | ||||||
| 2018-12-31 | 553.32K shares 10-K · filed 2020-03-19 | 28.11M shares 10-K · filed 2019-03-25 | ||||||
| 2018-09-30 | 556.65K shares 10-Q · filed 2019-11-12 | 9.28M shares 10-Q · filed 2018-11-08 | 556.65K shares 10-Q · filed 2019-11-12 | 9.44M shares 10-Q · filed 2018-11-08 | ||||
| 2018-06-30 | 569.08K shares 10-Q · filed 2019-08-14 | 9.45M shares 10-Q · filed 2018-08-09 | 569.08K shares 10-Q · filed 2019-08-14 | 9.45M shares 10-Q · filed 2018-08-09 | ||||
| 2018-03-31 | 9.42M shares 10-Q · filed 2019-05-06 | |||||||
| 2017-12-31 | 9.34M shares 10-K · filed 2019-03-25 | |||||||
| 2017-09-30 | 10.35M shares 10-Q · filed 2018-11-08 | 9.87M shares 10-Q · filed 2018-11-08 | ||||||
| 2017-06-30 | 8.73M shares 10-Q · filed 2018-08-09 | 8.73M shares 10-Q · filed 2018-08-09 | ||||||
| 2017-03-31 | 896.63K shares 10-Q · filed 2018-05-15 | 895.50K shares 10-Q · filed 2017-05-15 | ||||||
| 2016-12-31 | 851.16K shares 10-K · filed 2018-03-14 | 8.50M shares 10-K · filed 2017-03-27 | ||||||
| 2016-09-30 | 318.04K shares 10-Q · filed 2017-11-14 | 3.18M shares 10-Q · filed 2016-11-10 | 211.66K shares 10-Q · filed 2017-11-14 | 2.12M shares 10-Q · filed 2016-11-10 | ||||
| 2016-06-30 | 211.87K shares 10-Q · filed 2017-08-14 | 211.87K shares 10-Q · filed 2017-08-14 | 3.18M shares 10-Q · filed 2016-08-15 | |||||
| 2016-03-31 | 978.05K shares 10-Q · filed 2017-05-15 | 9.78M shares 10-Q · filed 2016-05-12 | ||||||
| 2015-12-31 | 8.85M shares 10-K · filed 2017-03-27 | |||||||
| 2015-09-30 | 1.52M shares 10-Q · filed 2016-11-10 | 1.44M shares 10-Q · filed 2016-11-10 | 3.35M shares 10-Q · filed 2015-11-16 | |||||
| 2015-06-30 | 528.35K shares 10-K · filed 2016-03-30 | 3.23M shares 10-Q · filed 2016-08-15 | ||||||
| 2015-03-31 | 10.38M shares 10-Q · filed 2016-05-12 | 99.49M shares 10-Q · filed 2015-05-15 | ||||||
| 2014-12-31 | 1.37M shares 10-K · filed 2015-04-15 | |||||||
| 2014-09-30 | 844.34K shares 10-K · filed 2016-03-30 | 817.24K shares 10-K · filed 2016-03-30 | 255.28K shares 10-Q · filed 2015-11-16 | |||||
| 2014-06-30 | 879.99K shares 10-K · filed 2016-03-30 | 879.99K shares 10-K · filed 2016-03-30 | 2.85M shares 10-Q · filed 2015-08-13 | |||||
| 2014-03-31 | 132.69M shares 10-Q · filed 2015-05-15 | 152.46M shares 10-Q · filed 2014-05-20 | ||||||
| 2013-12-31 | 77.49M shares 10-Q/A · filed 2015-04-15 | 54.49M shares 10-Q · filed 2014-05-20 | ||||||
| 2013-09-30 | 150.28M shares 10-Q/A · filed 2015-04-15 | 63.16M shares 10-Q/A · filed 2015-04-15 | ||||||
| 2013-06-30 | 24.98M shares 10-Q/A · filed 2015-04-15 | 22.35M shares 10-Q/A · filed 2015-04-15 | ||||||
| 2013-03-31 | 20.00M shares 10-Q/A · filed 2015-04-15 | 24.86M shares 10-Q · filed 2014-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |